BioMidwest
Filter News
Found 56,182 articles
-
Nicole Fevrier Davis Opens New MindBody Mastery Studio and Adds Psychic Assessments and Neurofeedback to her List of Unique Fitness Training Services
5/1/2018
Psychic personal trainer Nicole Fevrier Davis is slated to open her new studio at 10 Roberts Lane in Ridgefield CT on May 2nd.
-
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
-
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
5/22/2018
AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease.
-
The Prevalence of Childhood Poverty is Not Well Understood by Many Americans, New Survey Shows
5/22/2018
New Walgreens survey aims to raise childhood poverty awareness in advance of Red Nose Day in the U.S., May 24
-
Model Estimates Lifetime Risk Of Alzheimer's Dementia Using Biomarkers For Preclinical Disease
5/22/2018
Study finds lifetime risk of developing Alzheimer's varies by age, gender; First estimates that include biomarkers.
-
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
5/22/2018
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator
-
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
5/22/2018
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its third quarter of financial year 2018.
-
BioGenerator and Kingdom Capital Lead $2.4 Million Series A Venture Capital Financing for Canopy Biosciences
5/22/2018
Startup to Advance Research Tools Development and Add Jobs
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital
5/21/2018
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors (Board) in connection with a cooperation agreement with Engaged Capital, LLC ("Engaged Capital").
-
Cleveland Clinic and Brooks Automation Announce New Biobanking Facility
5/21/2018
New facility increases Clinic's capacity to analyze patient samples, advance medical research and enhance clinical care
-
Navitus Health Solution's Statement on Trump Administration's Prescription Drug Cost-Reduction Plan
5/21/2018
In response to the Trump administration's plan to reduce prescription drug costs, Navitus Health Solutions issued this response
-
Nautilus Medical Expands into Silicon Valley
5/21/2018
The new office expansion will enable Nautilus Medical to accommodate rapid growth and leverage the area's diverse high-technology talent pool while strengthening existing partnerships with Google, Samsung and Breast We Can.
-
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
-
Centene Subsidiary Awarded Correctional Healthcare Contract In Tucson, Arizona
5/18/2018
The contract will be administered by the County's Department of Behavioral Health and is expected to commence July 1, 2018, with a base term of three years, plus two optional years to renew.
-
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
-
EnvisionRx Prioritizes Opioid Safety with Multi-Faceted Pain Management Program
5/17/2018
Pharmacy benefit manager’s enhanced program helps payers safely address members' pain and lower risk of abuse Program helps educate and guide patients prescribed opioids to safely use these powerful drugs
-
CHEST simulation center awarded $3 million in equipment donation
5/17/2018
Olympus Corporation of the Americas provides equipment for the CHEST Innovation, Simulation, and Training Center with its charitable contribution
-
Two Prime Therapeutics Programs Associated with Improved Adherence for Medicare Members Using Cholesterol, Diabetes and Hypertension Drugs
5/16/2018
Lower generic cost share, missed refill interventions may yield better health, higher Star Ratings
-
FluGen Begins Enrollment of Clinical Trial of Novel Investigational Influenza Vaccine Against Multi-Season Mismatched Strains
5/16/2018
—Investigational vaccine designed to generate broad and durable immune protection over multiple influenza seasons —Subjects challenged with influenza virus genetically drifted by six years from vaccine strain —Study supported by U.S. Department of Defense